文献速递甲状腺疾病

索拉非尼治疗日本局部晚期或转移性甲状腺髓样癌及甲状腺未分化癌患者

Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2017-07-24

一项非对照、开放标签、多中心、单臂2期研究纳入18例日本患者(甲状腺髓样癌8例,甲状腺未分化癌10例),评估索拉非尼400 mg每日两次口服的安全性。最常见药物相关不良事件为手足皮肤反应(72%)、脱发(56%)、高血压(56%)和腹泻(44%)。甲状腺未分化癌患者中位无进展生存期2.8个月、中位总生存期5.0个月,客观缓解率0%、疾病控制率40%;甲状腺髓样癌患者中位无进展生存期和总生存期均未达到,客观缓解率25%、疾病控制率75%。作者认为索拉非尼对晚期甲状腺髓样癌似乎有效,对甲状腺未分化癌无效。

要点

  • 索拉非尼400 mg每日两次口服,常见药物相关不良事件为手足皮肤反应72%、脱发56%、高血压56%、腹泻44%。
  • 甲状腺未分化癌患者中位无进展生存期2.8个月,中位总生存期5.0个月,客观缓解率0%,疾病控制率40%。
  • 甲状腺髓样癌患者中位无进展生存期和总生存期均未达到,客观缓解率25%,疾病控制率75%。

核心结论

  • 本研究报道的毒性反应与索拉非尼已知安全性特征一致。
  • 索拉非尼似乎对晚期甲状腺髓样癌有效,但对甲状腺未分化癌无效,可能成为局部晚期或转移性甲状腺髓样癌及放射性碘难治性分化型甲状腺癌的新治疗选择。

研究设计与样本

  • 研究为非对照、开放标签、多中心、单臂2期临床研究。
  • 2014年4月至2014年9月入组组织学确诊的甲状腺未分化癌及局部晚期或转移性甲状腺髓样癌日本患者。
  • 共筛查20例患者,入组18例(甲状腺髓样癌8例,甲状腺未分化癌10例)。
  • 患者接受索拉非尼400 mg口服每日两次持续给药,直至疾病进展、不可接受毒性或撤回知情同意。
  • 主要终点为评估索拉非尼的安全性;次要终点包括无进展生存期、总生存期、客观缓解率、疾病控制率和肿瘤最大缩小程度。

主要发现

  • 最常见药物相关不良事件为手足皮肤反应(72%)、脱发(56%)、高血压(56%)和腹泻(44%)。
  • 甲状腺未分化癌患者中位无进展生存期为2.8个月[置信区间0.7-5.6],中位总生存期为5.0个月[置信区间0.7-5.7]。
  • 甲状腺未分化癌患者客观缓解率为0%,疾病控制率为40%。
  • 甲状腺髓样癌患者中位无进展生存期和中位总生存期在分析时均未达到。
  • 甲状腺髓样癌患者客观缓解率为25%,疾病控制率为75%。

临床怎么用

  • 作者认为索拉非尼似乎对晚期甲状腺髓样癌有效,但对甲状腺未分化癌无效。
  • 作者认为索拉非尼可能成为局部晚期或转移性甲状腺髓样癌及放射性碘难治性分化型甲状腺癌的新治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC). An uncontrolled, open-label, multicenter, single-arm, Phase 2 clinical study was conducted to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC. METHODS: Japanese patients with histologically confirmed ATC and locally advanced or metastatic MTC were enrolled from April to September 2014. The primary endpoint was to evaluate the safety of sorafenib. Treatment efficacy variables including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and maximum reduction in tumor size were evaluated as secondary endpoints. Patients received sorafenib 400 mg orally twice daily on a continuous basis and then continued treatment until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent. RESULTS: A total of 20 patients were screened, and 18 (8 with MTC and 10 with ATC) were enrolled. The most common drug-related adverse events were palmar-plantar erythrodysesthesia (72%), alopecia (56%), hypertension (56%), and diarrhea (44%). In the ATC patients, median PFS was 2.8 months [confidence interval 0.7-5.6], and median OS was 5.0 months [confidence interval 0.7-5.7]; ORR and DCR were 0% and 40%, respectively. In the MTC population, neither median PFS nor OS had been reached at the time of this analysis; ORR was 25% and DCR was 75%. CONCLUSIONS: The toxicities reported in this study were consistent with the known safety profile of sorafenib. Sorafenib seems to be effective in the treatment of advanced MTC but not ATC, and could be a new treatment option for locally advanced or metastatic MTC and radioactive iodine-refractory DTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ito Y, Onoda N, Ito KI, et al. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Thyroid. 2017. PMID: 28635560. doi:10.1089/thy.2016.0621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。